VIBRAMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vibramycin, and when can generic versions of Vibramycin launch?
Vibramycin is a drug marketed by Pfizer and is included in four NDAs.
The generic ingredient in VIBRAMYCIN is doxycycline calcium. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the doxycycline calcium profile page.
Summary for VIBRAMYCIN
Recent Clinical Trials for VIBRAMYCIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Iowa | Phase 4 |
Merck Sharp & Dohme Corp. | Phase 1 |
BioMed Valley Discoveries, Inc | Phase 1 |
Pharmacology for VIBRAMYCIN
Drug Class | Tetracycline-class Drug |
Anatomical Therapeutic Chemical (ATC) Classes for VIBRAMYCIN
US Patents and Regulatory Information for VIBRAMYCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | VIBRAMYCIN | doxycycline hyclate | CAPSULE;ORAL | 050007-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | VIBRAMYCIN | doxycycline hyclate | INJECTABLE;INJECTION | 050442-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | VIBRAMYCIN | doxycycline hyclate | CAPSULE;ORAL | 050007-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Pfizer | VIBRAMYCIN | doxycycline | FOR SUSPENSION;ORAL | 050006-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Pfizer | VIBRAMYCIN | doxycycline calcium | SUSPENSION;ORAL | 050480-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | VIBRAMYCIN | doxycycline hyclate | INJECTABLE;INJECTION | 050442-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VIBRAMYCIN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pfizer Limited | Doxirobe | Doxycycline | EMEA/V/C/000044 Treatment of periodontal disease in dogs.Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy. |
Withdrawn | no | no | no | 1999-09-16 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |